The latest data of abutinib was announced at the 63rd Annual Meeting of the American Society of Hematology (ASH)

Beijing, December 13, 2021/PRNewswire/ - Biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) announced today that experts will be present at the 63rd American Society of Hematology (ASH) Annual Meeting The latest data on Bruton’s tyrosine kinase (BTK) inhibitor obritinib was published on the report

The results of the Waldenstrom's macroglobulinemia study led by Professor Zhou Daobin were selected as oral presentations, the updated study results of chronic lymphocytic leukemia/small lymphocytic lymphoma led by Professor Li Jianyong and the primary immune thrombocytopenia conducted by Professor Ming Hou The results of the research were selected as poster presentations

Oral report

The effectiveness and safety of abutinib in patients with relapsed/refractory Waldenstrom's macroglobulinemia (abstract code: 46)

This study was conducted in patients with relapsed/refractory Waldenstrom's macroglobulinemia (R/R WM) to evaluate the efficacy and safety of oral abutinib

The median duration of treatment was 13.

Common adverse events include thrombocytopenia, neutropenia, leukopenia, and upper respiratory tract infections

Professor Zhou Daobin, Director of the Department of Hematology, Peking Union Medical College Hospital, said: “During short-term follow-up, abutinib has shown remarkable effectiveness in treating patients with relapsed/refractory WM

Poster presentation 1:

Obstinib monotherapy for patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Phase II study long-term follow-up results update (abstract code: 2638)

The following is an update of the long-term results of the Phase II study of obatinib in the treatment of R/R CLL/SLL:

A total of 80 R/R CLL/SLL patients were enrolled in this study

The overall response rate (ORR) evaluated by the investigator was 93.

During a similar median follow-up period, compared with other BTK inhibitors, abutinib treatment of R/R CLL/SLL has a higher CR/CRi rate

After the extended follow-up event, no new safety issues emerged

Professor Xu Wei, deputy director of the Department of Hematology, Jiangsu Provincial People’s Hospital, said: “This updated research result further confirms that compared with other BTK inhibitors, abutinib has a higher CR rate and faster in the treatment of R/R CLL patients.

Poster presentation 2:

Selective BTK inhibitor obritinib for the treatment of primary immune thrombocytopenia (abstract code: 3172)

Immune Thrombocytopenia (ITP) is the most common autoimmune bleeding disorder, which is characterized by an isolated peripheral platelet count reduction without a clear cause

Obutinib significantly inhibits the expression of BCR signal pathway activation markers CD69 and CD86 on peripheral blood B cells of patients with ITP in vitro, and also significantly reduces the number of CD138+ plasma cells

In the active ITP mouse model, the platelet counts of the mice in the abutinib treatment group were significantly higher than those in the control group on the 14, 21, and 28 days after splenocyte infusion

Professor Ming Hou, Director of the Tumor Center and Director of the Department of Hematology, Qilu Hospital of Shandong University, said: “Obutinib can effectively inhibit the activation and differentiation of B cells both in vivo and in vitro, thereby reducing thrombocytopenia in an active ITP mouse model

About Obutinib

Obutinib is a class 1 innovative drug independently developed by Nuocheng Jianhua.

Obutinib was approved in China on December 25, 2020 for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and relapsed/refractory mantle cell lymphoma ( MCL) Two indications
.
In addition, abutinib is also in China to treat marginal zone lymphoma (MZL), central nervous system lymphoma (CNSL), Waldenstrom's macroglobulinemia (WM) and diffuse large B-cell lymphoma (DLBCL) Including clinical trials of a variety of B-cell lymphomas
.

Obutinib was granted Breakthrough Therapy Designation by the Food and Drug Administration (FDA) in the United States for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL)
.

Based on its excellent target selection and clinical safety, abutinib is carrying out a global phase II clinical study for the treatment of multiple sclerosis (MS) in the field of autoimmune diseases, as well as the treatment of systemic lupus erythematosus (SLE) and primary immunity Phase II Chinese clinical trial of ITP
.

About Nuocheng Jianhua

Nuocheng Jianhua is a commercialized biomedical high-tech company focusing on the development of a class of new drugs in the treatment of malignant tumors and autoimmune diseases, suitable for the treatment of lymphoma, solid tumors and autoimmune diseases
.
Several new drug products are currently in commercialization, clinical and pre-clinical research and development stages
.
The company has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, New Jersey and Boston
.